237 related articles for article (PubMed ID: 16210385)
21. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G;
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):951s-8s. PubMed ID: 15701892
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Duffy SR; Taylor L
Am J Obstet Gynecol; 2004 Dec; 191(6):1921-7. PubMed ID: 15592273
[TBL] [Abstract][Full Text] [Related]
23. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
24. Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Bonanni B; Serrano D; Gandini S; Guerrieri-Gonzaga A; Johansson H; Macis D; Cazzaniga M; Luini A; Cassano E; Oldani S; Lien EA; Pelosi G; Decensi A
Clin Cancer Res; 2009 Nov; 15(22):7053-60. PubMed ID: 19887477
[TBL] [Abstract][Full Text] [Related]
25. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Aapro MS; Forbes JF
Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
[TBL] [Abstract][Full Text] [Related]
27. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
28. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
30. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
31. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
32. Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Needleman SJ; Tobias JS
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1871-81. PubMed ID: 19046107
[TBL] [Abstract][Full Text] [Related]
33. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
[TBL] [Abstract][Full Text] [Related]
34. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Dowsett M; Cuzick J; Wale C; Howell T; Houghton J; Baum M
J Clin Oncol; 2005 Oct; 23(30):7512-7. PubMed ID: 16234518
[TBL] [Abstract][Full Text] [Related]
36. New developments in the treatment of postmenopausal breast cancer.
Howell A
Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Ingle JN
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
[TBL] [Abstract][Full Text] [Related]
38. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Boccardo F; Guglielmini P; Bordonaro R; Fini A; Massidda B; Porpiglia M; Roagna R; Serra P; Orzalesi L; Ucci G; Rubagotti A
Eur J Cancer; 2013 May; 49(7):1546-54. PubMed ID: 23415888
[TBL] [Abstract][Full Text] [Related]
39. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
40. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Buzdar A
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S42-8. PubMed ID: 12756078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
